HC Wainwright Reaffirms “Buy” Rating for Moleculin Biotech (NASDAQ:MBRX)

HC Wainwright reiterated their buy rating on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note issued to investors on Monday,Benzinga reports. They currently have a $8.00 target price on the stock.

A number of other equities analysts have also issued reports on the company. Maxim Group lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. StockNews.com started coverage on Moleculin Biotech in a research report on Tuesday, February 25th. They issued a “sell” rating on the stock.

Moleculin Biotech Trading Down 10.9 %

Shares of NASDAQ:MBRX opened at $1.15 on Monday. Moleculin Biotech has a 1 year low of $0.40 and a 1 year high of $10.35. The stock has a 50-day simple moving average of $1.53 and a 200-day simple moving average of $2.15.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.